Summary
The prognostic value of tumoural epidermal growth factor receptor (EGFR), p53, thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) was analysed on 82 advanced head and neck cancer patients (71 men, 11 women; mean age 59). Induction treatment was cisplatin–5-FU ± folinic acid (61 patients, Chem group) or concomitant cisplatin–5-FU–radiotherapy (21 patients, RChem group). EGFR (binding assay), p53 protein (Sangtec immunoluminometric assay), TS and DPD activities (radioenzymatic assays) were measured on biopsies obtained at time of diagnosis. Significant positive correlation was demonstrated between p53 and EGFR. In the RChem group, p53 was higher in non-complete responders (median 1.03 ng mg–1) than in complete responders (median 0.08 ng mg–1) (P = 0.057). Univariate Cox analyses stratified on treatment group showed that specific survival (33 events) was significantly related to T staging, p53 taken as continuous or categorial (below vs over 0.80 ng mg–1) variable, and EGFR (below vs over 220 fmol mg–1); survival increased when EGFR and p53 were below thresholds. Multivariate stepwise analysis including T staging, EGFR and p53 revealed that T staging and EGFR were independent predictors of survival; relative risks were 3.68 for T staging and 2.65 for EGFR. Overall, EGFR remained an independent prognostic factor when response to treatment and T staging were considered in the multivariate analysis.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Beck, A., Etienne, M. C., Cheradame, S., Fischel, J. L., Formento, P., Renée, N. & Milano, G. (1994). A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur J Cancer 30: 1517–1522.
Chu, E. & Allegra, C. J. (1996). The role of thymidylate synthase in cellular regulation. Adv Enzyme Regul 36: 143–163.
Dassonville, O., Formento, J. L., Francoval, M., Ramaioli, A., Santini, J., Schneider, M., Demard, F. & Milano, G. (1993). Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 11: 1873–1878.
Dimery, I. W. & Hong, W. K. (1993). Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 85: 95–111.
Etienne, M. C., Bernard, S., Fischel, J. L., Formento, P., Gioanni, J., Santini, J., Demard, F., Schneider, M. & Milano, G. (1991). Dose reduction without loss of efficacy for 5 fluorouracil and cisplatin combined with folinic acid. In vitro study on human head and neck carcinoma cell lines. Br J Cancer 63: 372–377.
Etienne, M. C., Cheradame, S., Fischel, J. L., Formento, P., Dassonville, O., Renee, N., Schneider, M., Thyss, A., Demard, F. & Milano, G. (1995). Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13: 1663–1670.
Greenblatt, M. S., Bennett, W. P., Hollstein, M. & Harris, C. C. (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855–4878.
Harari, M. P. (1997). Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practise? J Clin Oncol 15: 2050–2055.
Harris, B. E., Song, R. & Soong, S. (1990). Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197–201.
Harris, C. C. (1996). Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88: 1442–1455.
Hasegawa, M., Mitsuhashi, N., Yamakawa, M., Furuta, M., Maebayashi, K., Imai, R., Hayakawa, K. & Niibe, H. (1997). p53 protein expression and radiation- induced apoptosis in human tumors transplanted to nude mice. Radiat Med 15: 171–176.
Johnston, P. G., Fischer, E. R., Rockette, H. E., Fischer, B., Wolmark, N., Drake, J. C., Chabner, B. A. & Allegra, C. J. (1994). The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640–2647.
Johnston, P. G., Mick, R., Recant, W., Beham, K. A., Dolan, M. E., Ratain, M. J., Beckmann, E., Weichselbaum, R. R., Allegra, C. J. & Vokes, E. E. (1997). Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 89: 308–313.
Koch, W. M., Brennan, J. A., Zahuvak, M., Goodman, S. N., Westra, W. H., Schwab, D., Yoo, G. H., Lee, D. J., Forastiére, A. A. & Sidransky, D. (1996). p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J Natl Cancer Inst 88: 1580–1586.
Lejebvre, J. L., Chevalier, D., Luboinski, B., Kirkpatrick, A., Colletti, L. & Sahmoud, T. (1996). Larynx preservation in pyriform sinus cancer. Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 88: 890–899.
Ludes-Meyers, J. H., Subler, M. A., Shirakumar, C. V., Munoz, R. N., Jiang, P., Bigger, J. E., Brown, D. R., Deb, S. P. & Deb, S. (1996). Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol Cell Biol 16: 6009–6019.
Mauzizi, M., Almadori, G., Ferrandina, G., Distefano, M. l., Romanini, M. E., Cadoni, G., Benedetti-Panici, P., Saludetti, B., Scambia, G. & Mancuso, S. (1996). Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 74: 1253–1257.
Mendelsohn, J. (1997). Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3: 2703–2707.
Pestalozzi, B. C., Peterson, H. F., Gelber, R. D., Goldhirsch, A., Gusterson, B. A., Trihia, H., Lindtner, J., Cortes-Funes, H., Simmoncini, E., Byzne, M. S., Gorlouh, R., Rudenstam, C. M., Castighione-Gertsh, M., Allegra, C. J. & Johnston, P. G. (1997). Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 15: 1923–1931.
Raybaud-Diogène, H., Tetu, B., Morenay, R., Fortin, A. & Monteil, R. A. (1996). p53 overexpression in head and neck squamous cell carcinoma; review of the literature. Oral Oncol, Eur J Cancer 32B: 143–149.
Rude Voldborg, B., Damstrup, L., Spang-Thomsen, M., Skovgaard & Poulsen, H. (1997). Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8: 1197–1206.
Santini, J., Milano, G., Thyss, A., Renée, N., Viens, P., Ayela, P., Schneider, M. & Demard, F. (1989). 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 59: 287–290.
Santini, J., Formento, J. L., Framcoual, M., Milano, G., Schneider, M., Dastonville, O. & Demard, F. (1991). Characterization, quantification and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 13: 132–139.
Spaulding, M. B., Fischer, S. G. & Wolf, G. T. (1994). Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. J Clin Oncol 12: 1592–1599.
Spears, C. P. & Gustavsson, B. G. (1988). Methods for thymidylate synthase pharmacodynamics: serial biopsy, free and total TS, FdUMP and dUMP, and H4 Pteglu and CH2-H4 Pteglu assays. In The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy, Rustum Y and McGuire JJ (eds), pp. 97–104. Plenum Press, New York
Störkel, S., Reichert, T., Reiffen, K. A. & Wagner, W. (1993). EGFR and PCNA expression in oral squamous cell carcinomas – a valuable tool in estimating the patient’s prognosis. Eur J Cancer 29B: 273–277.
Vokes, E. E., Weichselbaum, R. R., Lippman, S. M. & Hong, W. K. (1993). Head and neck cancer. N Engl J Med 328: 184–194.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Etienne, M., Pivot, X., Formento, J. et al. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil. Br J Cancer 79, 1864–1869 (1999). https://doi.org/10.1038/sj.bjc.6690297
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690297
Keywords
This article is cited by
-
A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma
Scientific Reports (2018)
-
Role of EGFR as a prognostic factor for survival in head and neck cancer: a meta-analysis
Tumor Biology (2014)
-
Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study
British Journal of Cancer (2014)
-
Tetraspanins CD9 and CD151, epidermal growth factor receptor and cyclooxygenase-2 expression predict malignant progression in oral epithelial dysplasia
British Journal of Cancer (2013)
-
Ron tyrosine kinase receptor synergises with EGFR to confer adverse features in head and neck squamous cell carcinoma
British Journal of Cancer (2013)